Nicotinamide: A cardioprotective form of  Vitamin B3

Qingyou Du

doi:10.5937/arhfarm74-52867

Qingyou Du University of Dundee, School of Medicine, Molecular and Clinical Medicine

DOI: https://doi.org/10.5937/arhfarm74-52867

Ključne reči: kardioprotekcija, nikotinamid

Sažetak

Nikotinamid, oblik vitamina B3, zapažen je kao potencijalni kardioprotektivni agens kod ishemijsko-reperfuzijske (I/R) povrede, koja je ključni faktor u patogenezi infarkta miokarda, srčane insuficijencije i drugih kardiovaskularnih bolesti. Ovo jedinjenje igra značajnu ulogu u energetskom metabolizmu, popravci DNK i preživljavanju ćelija tako što učestvuje u biosintezi NAD+, koenzima esencijalnog za redoks reakcije. U osnovi kardioprotekcije koju pruža nikotinamid leži mehanizam koji uključuje pojačanu biosintezu NAD+, koja zatim reguliše SUR2A kako bi se modulisali ATP-senzitivni K+ (KATP) kanali, utiče na aktivnost sirtuina i deluje na aktivnost poli(ADP-riboza) polimeraza (PARP) kako bi se očuvali nivoi NAD+. Pored toga, nikotinamid ispoljava antiinflamatorna svojstva, reguliše autofagiju i deluje antioksidativno, što zajedno doprinosi njegovom potencijalu da ublaži uticaj I/R povrede na miokard.Top of Form Uprkos širokom spektru terapijskih primena i sigurnom profilu, od ključnog je značaja imati na umu razlike između nikotinamida i druge forme vitamina B3, nikotinske kiseline (niacina), posebno u pogledu njihovih efekata na lipidni status i vaskularne funkcije. Za razliku od niacina, nikotinamid ne utiče na nivoe lipida niti povećava rizik od kardiovaskularnih događaja, što naglašava njegovu sigurnost za kliničku upotrebu u preporučenim dozama. Ipak, do sada nije sprovedena nijedna klinička studija o nikotinamidu u kontekstu kardioprotekcije. Jasno je da su potrebna randomizovana kontrolisana ispitivanja kako bi se ispitala moguća uloga nikotinamida u kliničkoj praksi, definisale optimalne strategije doziranja i razumeli njegovi dugoročni efekti. Međutim, s obzirom na istoriju upotrebe nikotinamida, ovo je jedinjenje koje bi moglo brzo biti uvedeno u kliničku praksu za kardioprotekciju.

Reference

Jovanović A. Cardioprotective signalling: Past, present and future. Eur J Pharmacol. 2018;833:314-319.

Freese R, Lysne V. Niacin - a scoping review for Nordic Nutrition Recommendations. Food Nutr Res. 2023;12:67.

Tannous C, Booz GW, Altara R, Muhieddine DH, Mericskay M, Refaat MM, Zouein FA. Nicotinamide adenine dinucleotide: Biosynthesis, consumption and therapeutic role in cardiac diseases. Acta Physiol (Oxf). 2021;231:e13551.

Zhang T, Xu L, Guo X, Tao H, Liu Y, Liu X, et al. The potential of herbal drugs to treat heart failure: The roles of Sirt1/AMPK. J Pharm Anal. 2024;14:157-176.

Zapata-Pérez R, Wanders RJA, van Karnebeek CDM, Houtkooper RH. NAD+ homeostasis in human health and disease. EMBO Mol Med. 2021;13:e13943.

Blanco-Vaca F, Rotllan N, Canyelles M, Mauricio D, Escolà-Gil JC, Julve J. NAD+-increasing strategies to improve cardiometabolic health? Front Endocrinol (Lausanne). 2022;12:815565.

Tosti G, Pepe F, Gnagnarella P, Silvestri F, Gaeta A, Queirolo P, Gandini S. The role of nicotinamide as chemo-preventive agent in NMSCs: A systematic review and meta-analysis. Nutrients. 2023;16:100.

Joshi M, Hiremath P, John J, Ranadive N, Nandakumar K, Mudgal J. Modulatory role of vitamins A, B3, C, D, and E on skin health, immunity, microbiome, and diseases. Pharmacol Rep. 2023;75:1096-1114.

Wu W, Yuan S, Tang Y, Meng X, Peng M, Hu Z, Liu W. Effect of exercise and oral niacinamide mononucleotide on improving mitochondrial autophagy in Alzheimer's Disease. Nutrients. 2023;15:2851.

Iqbal T, Nakagawa T. The therapeutic perspective of NAD+ precursors in age-related diseases. Biochem Biophys Res Commun. 2024;702:149590.

Crawford RM, Jovanović S, Budas GR, Davies AM, Lad H, Wenger RH, et al. Chronic mild hypoxia protects heart-derived H9c2 cells against acute hypoxia/reoxygenation by regulating expression of the SUR2A subunit of the ATP-sensitive K+ channel. J Biol Chem. 2003;278:31444-31455.

Du Q, Jovanović S, Sukhodub A, Jovanović A. Infection with AV-SUR2A protects H9C2 cells against metabolic stress: a mechanism of SUR2A-mediated cytoprotection independent from the K(ATP) channel activity. Biochim Biophys Acta. 2010;1803:405-415.

Mahdi H, Jovanović A. SUR2A as a base for cardioprotective therapeutic strategies. Mol Biol Rep. 2022;49:6717-6723.

Sukhodub A, Du Q, Jovanović S, Jovanović A. Nicotinamide-rich diet protects the heart against ischaemia-reperfusion in mice: a crucial role for cardiac SUR2A. Pharmacol Res. 2010;61:564-570.

Sukhodub A, Sudhir R, Du Q, Jovanović S, Reyes S, Jovanović A. Nicotinamide-rich diet improves physical endurance by up-regulating SUR2A in the heart. J Cell Mol Med. 2011;15:1703-1712.

Henning RJ, Bourgeois M, Harbison RD. Poly(ADP-ribose) Polymerase (PARP) and PARP inhibitors: Mechanisms of action and role in cardiovascular disorders. Cardiovasc Toxicol. 2018;18:493-506.

Meng Y, Song C, Ren Z, Li X, Yang X, Ai N, et al. Nicotinamide promotes cardiomyocyte derivation and survival through kinase inhibition in human pluripotent stem cells. Cell Death Dis. 2021;12:1119.

Li D, Wang X, Huang Q, Li S, Zhou Y, Li Z. Cardioprotection of CAPE-oNO2 against myocardial ischemia/reperfusion induced ROS generation via regulating the SIRT1/eNOS/NF-κB pathway in vivo and in vitro. Redox Biol. 2018;15:62-73.

Wang ZK, Chen RR, Li JH, Chen JY, Li W, Niu XL, et al. Puerarin protects against myocardial ischemia/reperfusion injury by inhibiting inflammation and the NLRP3 inflammasome: The role of the SIRT1/NF-κB pathway. Int Immunopharmacol. 2020;89:107086.

Ding X, Zhu C, Wang W, Li M, Ma C, Gao B. SIRT1 is a regulator of autophagy: Implications for the progression and treatment of myocardial ischemia-reperfusion. Pharmacol Res. 2024;199:106957.

Zhang T, Xu L, Guo X, Tao H, Liu Y, Liu X, et al. The potential of herbal drugs to treat heart failure: The roles of Sirt1/AMPK. J Pharm Anal. 2024;14:157-176.

Condori LDM, Vivas CV, Barreto YB, Gomes LF, Alencar AM, Bloise AC. Effects of Hypoxia and Reoxygenation on Metabolic Profiles of Cardiomyocytes. Cell Biochem Biophys. 2024. doi: 10.1007/s12013-024-01249-1. Epub ahead of print. PMID: 38498099.

Gille A, Bodor ET, Ahmed K, Offermanns S. Nicotinic acid: Pharmacological effects and mechanism of action. Ann Rev Pharmacol Toxicol. 2008;48:79-106.

AIM-HIGH Investigators; Boden WE, Probstfield JL, Anderson T, Chaitman BR, Desvignes-Nickens P, et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med. 2011;365:2255-2267. Erratum in: N Engl J Med. 2012;367:189.

Nikas IP, Paschou SA, Ryu HS. The role of nicotinamide in cancer chemoprevention and therapy. Biomolecules. 2020;10:477.

Crinò A, Schiaffini R, Manfrini S, Mesturino C, Visalli N, Beretta Anguissola G, et al. A randomized trial of nicotinamide and vitamin E in children with recent onset type 1 diabetes (IMDIAB IX). Eur J Endocrinol. 2004;150:719-724.

Maise K, Chong ZZ, Hou J, Shang YC. The vitamin nicotinamide: translating nutrition into clinical care. Molecules. 2009;14:3446-3485.

Niacin-Health Professional Fact Sheet [Internet] [cited 2024 Oct 10]. Available from: https://ods.od.nih.gov/factsheets/Niacin-HealthProfessional/.

Hwang ES, Song SB. Possible adverse effects of high-dose Nicotinamide: Mechanisms and safety assessment. Biomolecules. 2020;10:687.

Reagan-Shaw S, Nihal M, Ahmad N. Dose translation from animal to human studies revisited. FASEB J. 2008;22:659-661.

Cosmetic Ingredient Review Expert Panel. Final report of the safety assessment of niacinamide and niacin. Int J Toxicol. 2005;24 Suppl 5:1-31.

Huber R, Wong A. Nicotinamide: An update and review of safety & differences from niacin. Skin Therapy Lett. 2020;25:7-11.

Kaanders JH, Bussink J, van der Kogel AJ. ARCON: a novel biology-based approach in radiotherapy. Lancet Oncol. 2002;3:728-737.

Duncan KO, Stock EO, Damian DL, Miller SJ. Nicotinamide for high-risk skin cancer patients: An update. J Am Acad Dermatol. 2024;19:S0190-9622(24)02737-3.

Olmos PR, Hodgson MI, Maiz A, Manrique M, De Valdés MD, Foncea R, et al. Nicotinamide protected first-phase insulin response (FPIR) and prevented clinical disease in first-degree relatives of type-1 diabetics. Diabetes Res Clin Pract. 2006;71:320-333.

Crinó A, Schiaffini R, Ciampalini P, Suraci MC, Manfrini S, Visalli N, et al. A two year observational study of nicotinamide and intensive insulin therapy in patients with recent onset type 1 diabetes mellitus. J Pediatr Endocrinol Metab. 2005;18:749-754.

Overview on tolerable upper intake levels as derived by the Scientific Committee on Food (SCF) and the EFSA Panel on dietetic products, nutrition and allergies (NDA) [Internet] [cited 2024 Oct 10]. Available from: https://www.efsa.europa.eu/sites/default/files/2024-05/ul-summary-report.pdf.

B-3 Nicotinamide 500 mg 100 Vcaps [Internet] [cited 2024 Oct 10]. Available from: https://www.amazon.com/Nicotinamide-500-100-Vegetarian-Capsules/dp/B01M2CA564.

Vitamin B3 Nicotinamide 500mg 180 Capsules (Flush Free Niacin) Niacinamide [Internet] [cited 2024 Oct 10]. Available from: https://www.ebay.co.uk/itm/153088095839.

Nikotinamid: Kardioprotektivni oblik vitamina B3

Sažetak

Reference